EPISODE · Dec 28, 2023 · 35 MIN
PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape
from PeerView Clinical Pharmacology CME/CNE/CPE Video · host PVI, PeerView Institute for Medical Education
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
What this episode covers
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerPD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.Co-Chair/PlannerJonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
NOW PLAYING
PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape
No transcript for this episode yet
Similar Episodes
No similar episodes found.